PIK3CA and neoplasm: Recently, it has been raised the possibility that treatment with drugs used in other tumors, directed to mutations of PIK3CA or MTOR or amplification of CCND1, can also be used in metastasized parathyroid carcinoma, as these mutations are also frequent in this neoplasia.